Inactive Instrument

Northwest Biotherapeutics, Inc Stock OTC Bulletin Board

US66737P5017

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

Aug. 14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 06	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI

Valuation: Northwest Biotherapeutics, Inc

Market Cap	260M 231M 216M 197M 370M 25.03B 375M 2.61B 1.01B 12.76B 976M 955M 41.09B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	356M 317M 296M 270M 506M 34.29B 514M 3.57B 1.38B 17.48B 1.34B 1.31B 56.28B	EV / Sales 2026 *	-	EV / Sales 2027 *	9.89x
Free-Float	95.22%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news: Northwest Biotherapeutics, Inc

Aug. 14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 06	Northwest Biotherapeutics and Saudi Pharmaceutical Industries and Medical Appliance Company Enter Memorandum of Understanding for Collaboration	CI
Jul. 08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
May. 15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
Apr. 15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Apr. 14	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
Nov. 14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 13	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
25-10-31	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
25-10-26	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
25-10-23	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
25-08-26	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI

More news

Press Releases: Northwest Biotherapeutics, Inc

Aug. 14	Northwest Biotherapeutics: Q2 Earnings Snapshot	AQ
Aug. 06	Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company	PR
Jul. 08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
Jul. 02	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
May. 15	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ

More press releases

Managers and Directors: Northwest Biotherapeutics, Inc

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	2007-05-31
Linda Powers CEO	Chief Executive Officer	71	2011-06-07
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	1999-12-31

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	1997-12-31
Linda Powers CHM	Chairman	71	2007-05-16
Navid Malik BRD	Director/Board Member	57	2012-03-31

More insiders

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Maximize my profits

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.16%	-0.36%	+49.37%	+94.17%	74.46B
ARGENX SE	-0.61%	+0.69%	+36.36%	+82.72%	60.14B
LONZA GROUP AG	-2.54%	-0.21%	+6.34%	+31.72%	48.15B
IQVIA HOLDINGS INC.	-3.02%	-2.67%	+37.26%	+32.51%	44.25B
REVOLUTION MEDICINES, INC.	+0.31%	+7.94%	+340.88%	+643.82%	43.99B
BEONE MEDICINES AG	-1.96%	-1.71%	+5.30%	+99.46%	41.61B
CELLTRION, INC.	+3.32%	+3.49%	+11.18%	+51.23%	29.97B
WUXI BIOLOGICS (CAYMAN) INC.	+4.77%	+6.16%	+36.77%	+22.78%	29.31B
INSMED INCORPORATED	-4.86%	-8.24%	-24.60%	+330.06%	24.93B
Average	-0.05%	+1.97%	+55.43%	+154.28%	44.09B
Weighted average by Cap.	+0.17%	+1.83%	+60.06%	+145.78%

	2026 *	2027 *
Net sales	-	38.93M 34.63M 32.36M 29.51M 55.36M 3.75B 56.21M 391M 151M 1.91B 146M 143M 6.15B
Net income	-	-
Net Debt	96.08M 85.46M 79.85M 72.81M 137M 9.25B 139M 964M 374M 4.72B 361M 353M 15.19B	125M 111M 104M 94.68M 178M 12.03B 180M 1.25B 486M 6.13B 469M 459M 19.75B

Northwest Biotherapeutics, Inc Stock OTC Bulletin Board

Stocks

US66737P5017

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc

Latest news: Northwest Biotherapeutics, Inc

Press Releases: Northwest Biotherapeutics, Inc

Managers and Directors: Northwest Biotherapeutics, Inc

Bio Therapeutic Drugs

Financials

Company Profile